Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AK139 injection in prurigo nodularis
CTR20263884Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in prurigo nodularis (PN), sponsored by Akeso, Inc.. Started Oct 2026; status: active.
02
Drugs
AK139
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20263884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263884.